Key result
Ongoing studies of thrombin and PAR-1 inhibition will determine their potential to safely reduce myocardial infarction and death in high-risk patients with diabetes mellitus.
Why the study?
Does adding a PAR-1 inhibitor to aspirin and a P2Y12 inhibitor reduce rates of myocardial infarction and death without significantly compromising haemostasis in high-risk patients with diabetes mellitus?
Does adding a PAR-1 inhibitor to aspirin and a P2Y12 inhibitor reduce rates of myocardial infarction and death without significantly compromising haemostasis in high-risk patients with diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Ongoing studies will determine if adding thrombin or PAR-1 inhibitors to standard dual antiplatelet therapy can safely reduce atherothrombotic events in patients with diabetes.
Corresponding author: Robert F Storey, Department of Cardiovascular Science, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK. Email: r.f.storey@sheffield.ac.uk fibrillation will provide new information about the impact of thrombin inhibition on ischaemic events in diabetic compared with non-diabetic patients. Ongoing studies of the alternative strategy of targeting the principal platelet thrombin receptor, PAR-1, rather than thrombin itself will also reveal the potential of adding a further platelet inhibitor to aspirin and a P2Y 12 inhibitor in high-risk patients. This strategy has the advantage of more limited effects on haemostasis compared with anticoagulant therapies yet potentially synergistic antithrombotic effects and so the clinical trial results are eagerly awaited to determine whether it is possible to reduce rates of myocardial infarction and death without significantly compromising haemostasis. It is clear that the mechanisms by which diabetes mellitus drives increased propensity to thrombogenesis will continue to be unravelled in future work and our evolving scientific understanding will underpin new therapeutic strategies that reduce morbidity and mortality due to atherothrombosis in patients with diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Robert F. Storey (2010) conducted a review in Diabetes mellitus. Thrombin inhibition and PAR-1 antagonists was evaluated. Ongoing studies of thrombin and PAR-1 inhibition will determine their potential to safely reduce myocardial infarction and death in high-risk patients with diabetes mellitus.
Synapse has enriched 10 related papers. Consider them for comparative context: